Source comparison
Best BPC-157 Dosage Gastric Protection 2026: Administration Protocol Comparison
Oral (capsule/liquid) 250–500mcg Once or twice daily Direct mucosal contact, increased mucin and PGE2 secretion NSAID-induced ulcers, gastritis, prevention during chronic NSAID use Preferred for gastric-specific protection. Delivers peptide directly to damaged
This comparison does not assign a generated winner or score.
- Oral (capsule/liquid)
- 250–500mcg
- Once or twice daily
- Direct mucosal contact, increased mucin and PGE2 secretion
- NSAID-induced ulcers, gastritis, prevention during chronic NSAID use
- Preferred for gastric-specific protection. Delivers peptide directly to damaged tissue with superior mucosal adherence
- Subcutaneous injection
- Twice daily (every 12 hours)
- Systemic angiogenesis, VEGF upregulation, cytokine modulation
- Severe ulceration, concurrent systemic injury, inflammatory conditions
- Effective but less targeted. Systemic distribution dilutes gastric tissue concentration
- Combined oral + subcutaneous
- 250mcg oral + 250mcg SC
- Twice daily
- Dual pathway: local mucosal protection + systemic healing
- Refractory ulcers unresponsive to monotherapy, severe NSAID damage
- Theoretically superior but lacks robust clinical validation. Consider for complex cases only
- High-dose oral (therapeutic ceiling)
- 500–1000mcg
- Saturated mucosal contact, maximum PGE2 expression
- Acute bleeding ulcers, perforation risk, failed PPI therapy
- Reserve for severe cases under clinical oversight. Long-term safety data at this range remains limited
- Oral administration at 250–500mcg daily represents the research-validated standard for gastric protection. Higher doses or combined routes should be reserved for refractory cases where standard dosing fails to produce mucosal healing within 14–21 days.